Clinical trials: Rosuvastatin
Drug Interactions
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
The purpose of this study is to identify and validate a probe cocktail for use in future drug-drug interaction studies. Cytochrome P450 enzymes and transport proteins play important roles in the disposition of drugs.
- Trial name
- NCT00964106
- Testing
- Caffeine, Rosiglitazone, Flurbiprofen
- Where
- 2 sites in South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION
To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration
- Trial name
- REVORUTION (NCT00526721)
- Where
- 3 sites in South Korea
- Volunteers
- 1,482 people
- Sponsor
- AstraZeneca
Hypercholesterolaemia
Rosuvastatin Calcium Bioequivalence Study - Fast
This is an open-label, randomized, two treatment, two sequences, two periods crossover study, using a crossover 2x2 design, where each subject will be randomly assigned to reference or test formulation, in order to evaluate if…
- Trial name
- NCT01711749
- Testing
- Crestor®, rosuvastatin calcium tablets
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca